



[Science Education](#) [Patient Care & Advocacy](#)
[Our Society](#) [Our Mission, Vision & Values](#) [EBMT Membership 2020](#) [Organisational Structure 2020](#) [Financial Highlights 2020](#) [EBMT Partners](#)

Breadcrumb

1. [Home](#)

Entity Print



Bertram Glass

LWP Chair (elected May 2020, past chair: Silvia Montoto)

Germany

Major achievements

The LWP is an open and informal group of physicians, data-managers, statisticians, and nurses interested in lymphoma and cellular therapies. We invite any scientists, in particular younger colleagues entering the field, to join the LWP and help to fulfill our mission.

A major goal of this year's work was and probably will be in future years to assess the impact of CAR T-cells (CART) and other cellular and non-cellular therapies on the treatment landscape of lymphoma and the integration of these modalities into classical transplantation. While the more traditional work on classical transplant therapies continues (documented by the papers listed below) our main effort lies now on planning and executing of new projects in the aforementioned area. To be successful, a strong co-operation with other EBMT Working Parties is needed; in particular, the LWP's expertise in contributing to the GoCART coalition is recognized and developing. Educational initiative was always an important part of the work of the LWP.

In 2020, the Corona-pandemic negatively impacted on all the LWP activities; COVID-19 was prohibitive detrimental to all LWP activities relying on intensive personal interaction. Consequently, we had to postpone the annual LWP educational course to 2021. We also decided against a virtual educational course as we felt that the lively, interactive and stimulating atmosphere of this event could not be achieved in a virtual meeting.

Principal research studies

1. Allogeneic Transplantation in Double (Triple) - Hit Diffuse Large B-Cell Lymphoma: a retrospective study of the EBMT-Lymphoma Working Party. (PI.: P. Berning) .
2. Allogeneic and autologous transplantation in NK/ T-cell lymphoma (in cooperation with Chinese and Korean investigators) A retrospective analysis of transplant outcomes in the era of new and targeted therapies (PI: B. Friedrichs)
3. Recent results of autologous and allogeneic stem cell transplantation in patients with first relapse or refractory to first-line therapy. (PI: B. Glass)

Key publications

[2020](#)

[Cellular Immunotherapy for Refractory Diffuse Large B Cell Lymphoma in the Chimeric Antigen Receptor-Engineered T Cell Era: Still a Role for Allogeneic Transplantation?](#)
[Group](#)

[Lymphoma Working Party \(LWP\)](#)

[Other society](#)

[1st listed author](#)

[Dreger P](#)

[Journal](#)

[Biol Blood Marrow Transplant.](#)

[2020](#)

[Nonmyeloablative Alternative Donor Transplantation for Hodgkin and Non-Hodgkin Lymphoma: From the LWP-EBMT, Eurocord, and CIBMTR.](#)

[Group](#)

[Lymphoma Working Party \(LWP\)](#)

[Other society](#)

[1st listed author](#)

[Fatobene G](#)

[Journal](#)

[J Clin Oncol.](#)

[2020](#)

[Idelalisib Exposure Before Allogeneic Stem Cell Transplantation in Patients With Follicular Lymphoma: An EBMT Survey](#)

[Group](#)

[Chronic Malignancies Working Party \(CMWP\)](#)

[Lymphoma Working Party \(LWP\)](#)

[1st listed author](#)

[Leopold Sellner](#)

[Journal](#)

[Bone Marrow Transplant.](#)

[2020](#)

[Changes in patients population and characteristics of hematopoietic stem cell transplantation for relapsed/refractory Hodgkin lymphoma: an analysis of the Lymphoma Working Party of the EBMT.](#)

[Group](#)

[Lymphoma Working Party \(LWP\)](#)

[1st listed author](#)

[Anna Sureda](#)

[Journal](#)

[Bone Marrow Transplant.](#)

[2020](#)

[Second autologous stem cell transplantation for relapsed/refractory Hodgkin lymphoma after a previous autograft: a study of the lymphoma working party of the EBMT](#)

[Group](#)

[Lymphoma Working Party \(LWP\)](#)

[1st listed author](#)

[Carmen Martínez](#)


[Journal](#)

[Leuk Lymphoma.](#)

[See the full list of the LWP 2020 publications](#)



Impact factor
(Lymphoma)



	2015	2016	2017	2018	2019	2020
Oral presentations	6	3	8	8	7	1
Poster presentations	4	5	8	9	4	0

2015 2016 2017 2018 2019 2020

International educational events 4 6 3 1 1 1